lncsnhg：骨肉瘤的新靶点。

IF 5 3区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cancer gene therapy Pub Date : 2025-08-16 DOI:10.1038/s41417-025-00952-2

Yining Zhang, Jinfa Wu, Jiaming Liu

{"title":"lncsnhg：骨肉瘤的新靶点。","authors":"Yining Zhang, Jinfa Wu, Jiaming Liu","doi":"10.1038/s41417-025-00952-2","DOIUrl":null,"url":null,"abstract":"Long non-coding RNAs (lncRNAs) have attracted significant attention for their role in tumor initiation and progression. Specifically, studying lncRNA small nucleolar RNA host genes (lncSNHGs) has opened up new possibilities for the treatment of osteosarcoma (OS). This review aims to give a thorough overview of the state of research on the biological roles, molecular mechanisms, and expression of the lncRNA SNHG family in OS. Through an extensive analysis, it is demonstrated that members of the SNHG family exhibit dysregulated expression patterns in OS. These dysregulations affect multiple oncogenic processes, including tumor proliferation, metastasis, apoptosis, autophagy, and chemotherapy resistance. The lncRNA SNHG family promises to identify novel strategies and targets for diagnosing, treating, and prognosis OS.","PeriodicalId":9577,"journal":{"name":"Cancer gene therapy","volume":"32 10","pages":"1031-1041"},"PeriodicalIF":5.0000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LncSNHGs: new targets in osteosarcoma\",\"authors\":\"Yining Zhang, Jinfa Wu, Jiaming Liu\",\"doi\":\"10.1038/s41417-025-00952-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Long non-coding RNAs (lncRNAs) have attracted significant attention for their role in tumor initiation and progression. Specifically, studying lncRNA small nucleolar RNA host genes (lncSNHGs) has opened up new possibilities for the treatment of osteosarcoma (OS). This review aims to give a thorough overview of the state of research on the biological roles, molecular mechanisms, and expression of the lncRNA SNHG family in OS. Through an extensive analysis, it is demonstrated that members of the SNHG family exhibit dysregulated expression patterns in OS. These dysregulations affect multiple oncogenic processes, including tumor proliferation, metastasis, apoptosis, autophagy, and chemotherapy resistance. The lncRNA SNHG family promises to identify novel strategies and targets for diagnosing, treating, and prognosis OS.\",\"PeriodicalId\":9577,\"journal\":{\"name\":\"Cancer gene therapy\",\"volume\":\"32 10\",\"pages\":\"1031-1041\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer gene therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41417-025-00952-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer gene therapy","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41417-025-00952-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

长链非编码rna （lncRNAs）因其在肿瘤发生和发展中的作用而引起了人们的广泛关注。具体来说，研究lncRNA小核仁RNA宿主基因（lncSNHGs）为骨肉瘤（OS）的治疗开辟了新的可能性。本文就lncRNA SNHG家族在OS中的生物学作用、分子机制及表达等方面的研究现状进行综述。通过广泛的分析，证明SNHG家族成员在OS中表现出失调的表达模式。这些失调影响多种致癌过程，包括肿瘤增殖、转移、细胞凋亡、自噬和化疗耐药性。lncRNA SNHG家族有望确定诊断、治疗和预后OS的新策略和靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

LncSNHGs: new targets in osteosarcoma

查看原文本刊更多论文

LncSNHGs: new targets in osteosarcoma

Long non-coding RNAs (lncRNAs) have attracted significant attention for their role in tumor initiation and progression. Specifically, studying lncRNA small nucleolar RNA host genes (lncSNHGs) has opened up new possibilities for the treatment of osteosarcoma (OS). This review aims to give a thorough overview of the state of research on the biological roles, molecular mechanisms, and expression of the lncRNA SNHG family in OS. Through an extensive analysis, it is demonstrated that members of the SNHG family exhibit dysregulated expression patterns in OS. These dysregulations affect multiple oncogenic processes, including tumor proliferation, metastasis, apoptosis, autophagy, and chemotherapy resistance. The lncRNA SNHG family promises to identify novel strategies and targets for diagnosing, treating, and prognosis OS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer gene therapy 医学-生物工程与应用微生物

CiteScore

10.20

自引率

0.00%

发文量

150

审稿时长

4-8 weeks

期刊介绍： Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.